338 related articles for article (PubMed ID: 32345650)
1. Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Shao H; Shi L; Fonseca VA
Diabetes Care; 2020 Jul; 43(7):1530-1536. PubMed ID: 32345650
[TBL] [Abstract][Full Text] [Related]
2. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
3. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
4. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
5. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
7. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
9. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
10. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
12. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
Wong ND; Fan W; Pak J
Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
14. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
15. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
Si L; Willis MS; Asseburg C; Nilsson A; Tew M; Clarke PM; Lamotte M; Ramos M; Shao H; Shi L; Zhang P; McEwan P; Ye W; Herman WH; Kuo S; Isaman DJ; Schramm W; Sailer F; Brennan A; Pollard D; Smolen HJ; Leal J; Gray A; Patel R; Feenstra T; Palmer AJ
Value Health; 2020 Sep; 23(9):1163-1170. PubMed ID: 32940234
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
19. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
20. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]